Functional EP2 receptors on blast cells of patients with acute leukemia [3]

International Journal of Cancer

Volumn 115, Issue 3, 2005, Pages 499-501

  Denizot, Yves ^a   Donnard, Magali ^b   Truffinet, Véronique ^a   Malissein, Emilie ^c   Faucher, Jean Luc ^b   Turlure, Pascal ^b   Bordessoule, Dominique ^b   Trimoreau, Franck ^b  

^a CNRS   (France)

^b DUPUYTREN UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF LIMOGES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN EP2 RECEPTOR; PROSTAGLANDIN EP4 RECEPTOR; UNCLASSIFIED DRUG; OXYTOCIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; AGED; BLAST CELL; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; LETTER; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; BLAST CELL CRISIS; CELL CULTURE; CLASSIFICATION; METABOLISM; MYELOID LEUKEMIA; PATHOLOGY;

AGED; BLAST CRISIS; CYCLIC AMP; DINOPROSTONE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MALE; OXYTOCICS; RECEPTORS, PROSTAGLANDIN E; TUMOR CELLS, CULTURED;

EID: 18644376857     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20877     Document Type: Letter

References (15)

1. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol 2002;23:144-50.
2. Serhan CN, Levy B. Success of prostaglandin E2 in structure-function is a challenge for structure-based therapeutics. Proc Natl Acad Sci USA 2003;100:8609-11.
3. Denizot Y, Donnard M, Truffinet V, Turlure P, Faucher JL, Bordessoule D, Trimoreau F. Platelet-activating factor does not stimulate cAMP formation from immature forms of freshly isolated leukaemic blasts. Leuk Lymph 2005;46:129-31.
4. Mentz F, Merle-Beral H, Dalloul AH. Theophylline-induced B-CLL apoptosis is partly dependent on cyclic AMP production but independent of CD38 expression and endogenous IL-10 production. Leukemia 1999;13:78-84.
5. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977;74:5463-7.
6. Denizot Y, Pinaud E, Aupetit C, Le Morvan C, Magnoux E, Aldigier JC, Cogné M. Polymorphism of the human α1-immunoglobulin gene 3′ enhancer hs1, 2 and its relation to gene expression. Immunology 2001;103:35-40.
7. Smock SL, Pan LC, Castleberry TA, Lu B, Mather RJ, Owen TA. Cloning, structural characterization, and chromosomal localization of the gene encoding the human prostaglandin E(2) receptor EP2 sub-type. Gene 1999;237:393-402.
8. Regan JW, Bailey TJ, Pepperl DJ, Pierce KL, Bogardus AM, Donello JE, Fairbaim CE, Kedzie KM, Woodward DF, Gil DW. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol 1994;46:213-220.
9. + progenitors. Prostaglandins Other Lipid Mediat 1998;55:179-86.
10. Ishiguro S, Takahashi N, Nemoto K, Negishi M, Ichikawa A. Potentiation of retinoic acid-induced differentiation of HL-60 cells by prostaglandin EP2 receptor. Prostaglandins Other Lipid Mediat 1998;56:145-53.
11. Santini V, Colombat PH, Delwel R, van Gurp R, Touw I, Löwenberg B. Induction of granulocytic maturation in acute myeloid leukaemia by G-CSF and retinoid acid. Leuk Res 1991;15:341-50.
12. Tortorella C, Piazzolla G, Spaccavento F, Jirillo E, Antonaci S. Age-related effects of oxidative metabolism and cyclic AMP signalling on neutrophil apoptosis. Mech Age Dev 1999;110:195-205.
13. Yarovinsky TO, Hunninghake GW. Lung fibroblasts inhibit activation-induced death of T cells through PGE2-dependent mechanisms. Am J Physiol Lung Cell Mol Physiol 2001;281:L1248-56.
14. Secchiero P, Gonelli A, Ciabattoni G, Melloni E, Grill V, Rocca B, Delbello G, Giorgio Z. TNF-related apoptosis-inducing ligand (TRAIL) up-regulates cyclooxygenase (COX)-1 activity and PGE2 production in cells of the myeloid lineage. J Leukoc Biol 2002;72:986-94.
15. Dussault I, Miller SC. Effect on leukemia cell numbers of in vivo administration of immunotherapeutic agents is age-dependent. Oncology 1996;53:241-6.